NCE Pharma Patents Suven Life Sciences Four Secures Pharma Patents for NCEs

Editor: Dominik Stephan

Indian is not only a manufacturer of generic drugs – Indian companies also develop innovative new treatments. The most recent addition to the country's pharma portfolio are four foreign patents granted to Suven Life Sciences.

Related Company

(Picture: Suven)
(Picture: Suven)

Hyderabad/India – Suven Life Sciences secures four foreign pharma patents for their New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative illnesses. The patents from Europe Europe (EP 2155674), Srilanka (14612 & 14833) and Korea (1049868) are valid through 2027, 2025 and 2024 respectively.

Suven announced that the granted claims of these patents included the class of selective 5-HT compounds discovered by Suven that are recently being therapeutic agents for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

Venkat Jasti, CEO of Suven, is very content about this development: ”We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $30 billion market potential globally.” Suven now holds a total of eleven granted patents.